Researchers reported that simultaneously modulating STING, TGF‑β, and PD‑L1 pathways dramatically enhances antitumor immunity through activation of the CXCL16–CXCR6 axis. The triple-targeting approach increased immune infiltration and tumor control in preclinical models, according to the study authors. The strategy suggests new combination regimens that integrate innate immune activation (STING agonists), TGF‑β blockade, and checkpoint inhibition to convert cold tumors into inflamed, therapy-responsive microenvironments. Translational efforts will need to balance efficacy with overlapping toxicities and dose scheduling in clinical development.